CME online

in association with the 22nd Annual World Congress on Insulin Resistance Diabetes and Cardiovascular Disease -WCIRDC

The Complications of DCRM-Diabetes & CardioRenalMetabolic Patient

This is a CME Symposium Supported by an Educational Grant from AstraZeneca
Provided By:

Administrated by::
This CME online educational activity is approved for a maximum of 2.00 AMA PRA Category 2 Credit(s). and ABIM MOC

Accreditation period: January 20, 2025 - January 20, 2026

To get started:

Login / Register
CME information
View Agenda
Course presentation

To Receive a Certificate for This CME Activity:  

View the presentations in this CME activity and complete the evaluation. Your certificate will be mailed to you upon satisfactory completion of these documents.

The Complications of DCRM-Diabetes & CardioRenalMetabolic Patient
Agenda

Introduction & Pre-CME Questions
Stephen J. Greene, MD

Diabetes & CRM Approach to Comorbidities
Peter Rossing, MD, DMSc

Heart Failure & Cardiomyopathy- Addressing Etiologies
Michelle M. Kittleson, MD, PhD

The Treatment of CKD and Heart Failure Circa 2024
Katherine R. Tuttle, MD

Panel Discussion and Q&A:
The Physician’s Role in the Proper Diagnosis of DCRM Complications
Panel:
Stephen J. Greene, MD • Michelle M. Kittleson, MD, PhD • Peter Rossing, MD, DMSc • Katherine R. Tuttle, MD Moderator:
Yehuda Handelsman, MD

Faculty

Yehuda Handelsman, MD, Chair
FACP, FNLA, FASPC, FAHA, MACE

Medical Director & Principal Investigator
The Metabolic Institute of America
Chair Scientific Advisory Board
DCMi- Diabetes CardioRenal & Metabolism Institute
Chair & Program Director 22nd WCIRDC
Tarzana, California

Stephen J. Greene, MD, Chair

Associate Professor of Medicine, Division of Cardiology
Co-Director, Duke Heart Failure Medication
Titration Clinic
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina

Michelle M. Kittleson, MD, PhD

Professor of Medicine
Director of Education
in Heart Failure and Transplantation
Smidt Heart Institute, Cedars-Sinai
Los Angeles, CA

Katherine R. Tuttle, MD

Executive Director for Research, Providence Inland Northwest Health
Professor of Medicine, Division of Nephrology and Kidney Research Institute
Regional Principal Investigator
Institute of Translational Health Sciences
University of Washington

Peter Rossing, MD, DMSc

Professor, Department of Clinical Medicine
University of Copenhagen
Steno Diabetes Center Copenhagen
Herlev, Denmark

Program Description

Comorbidities of Obesity, diabetes namely Cardiorenal metabolic diseases are often not diagnosed or overlooked. Especially Chronic kidney disease (CKD) and heart failure (HF) which are not just under-diagnosed but generally under-treated. Failure to treat these conditions may lead to high risk of hospitalization and death. This satellite symposium will address the pathophysiology of these complications and explore strategies for correctly diagnosing and treating patients with obesity and diabetes who have cardiorenal-metabolic complications. The symposium will address gaps in physicians’ knowledge in diagnosing and managing these high risk patients.




Learning Objectives

Upon completion of this CME symposium, participants should be able to:

  • Describe the epidemiologic and pathophysiologic connections that link obesity, diabetes and cardiorenal comorbidities
  • Understand the etiology of Cardiomyopathy and Heart Failure
  • Review the use of SGLT2 inhibitors and in combination with RAS inhibitors, MRAs, and GLP-1 RAs in the management of HF and or CKD
  • The Physician’s Role in the Proper Diagnosis of DCRM Complications and administration of appropriate treatment of CKD, HF & cardiomyopathy

    • Target Audience

    This educational initiative is designed for cardiologists, nephrologists, endocrinologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of CKD and HF and prevention of morbidity and mortality.

    CME Statement

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.

    PESI, Inc, designated this live educational activity for a maximum of 2.00 AMA PRA Category 1 Credit(s).
    Physicians should only claim credit commensurate with the extent of their participation in the activity.